Lucy’s story: 7 years of harmful cancer treatment under Prof Ian Brown

Despite guidelines recommending a maximum of six chemotherapy cycles, Lucy was prescribed over 75 across seven years — long after her scans showed no evidence of progression.
We make the difference. Talk to us: 0333 004 4488 | hello@brabners.com
AuthorsFiona Tinsley

Head of Medical Negligence, Fiona Tinsley (second from right), alongside Paralegal Becky Addison (far right) and our clients Becky and Michael, who are being represented in relation to their treatment under the care of Professor Ian Brown and University Hospitals Coventry & Warwickshire NHS Trust
As seen on ITV's Good Morning Britain today, our lawyers — who are representing current and former patients of the University Hospitals Coventry and Warwickshire NHS Trust (UHCW) — are calling for an extended patient safety review and independent investigation into a chemotherapy regime that saw its oncology and pharmacy department routinely prescribe remarkably high incidences of toxic chemotherapy.

Last year, our investigation identified that numerous patients under the care of Professor Ian Brown had been exposed to prolonged and what they say, in some cases, was unnecessary use of the chemotherapy drug temozolomide over the past two decades. These cases specifically involved individuals with brain and spinal tumours.
Medical guidance states that the drug (temozolomide) — which carries severe side effects including extreme fatigue, confusion, sickness and seizures — should be used over a period of six months (and a maximum of 12 months). Our investigation uncovered that patients had been routinely prescribed the drug for several years and in many cases for more than a decade.
In some cases, the use of temozolomide was found in patients who were unable to conceive naturally, while others reported their inability to pursue career ambitions and normal day-to-day activities due to the debilitating nature of the chemotherapy regime, which involves significant recovery time. Independent expert assessments commissioned by the firm have identified cases where chemotherapy was said to have been entirely unnecessary and where patients are now undergoing treatment for secondary cancers linked to overuse of temozolomide.

Responses to the Freedom of Information requests we submitted show that UHCW spent more than £3.6m on Temozolomide between 2009 and 2024 — more than ten times that of comparable NHS hospitals.
With well over 20 cases already ongoing and more patients emerging all the time, we're calling for an independent inquiry into practices at this Trust — and in particular, treatment under the care of Professor Brown dating back to 2006.
UHCW has been conducting an internal patient safety review since January covering the period between 2017 and Professor Brown’s retirement in 2023.
Our Head of Medical Negligence, Fiona Tinsley, said: "The extent of this scandal, and the physical and mental impact it has had on Professor Brown’s patients cannot be underestimated. It is our clear view that all the patients represented by Brabners have been subjected to negligent treatment — treatment which they were led to believe was keeping them alive. Through our campaign, they are only now realising that much of this treatment deviated wildly from established medical guidance and, in some instances, the ‘treatment’ was entirely unnecessary.
We believe there are many more patients out there who haven’t yet come forward and some who may have sadly passed away.
While we welcome the ongoing investigations currently being undertaken by the General Medical Council and Royal College of Physicians, we believe a full independent inquiry is necessary — including an extension of the Trust’s own review back to 2006 — not only to ensure justice for victims, but that processes are put in place to better identify and prevent such failings happening again".

Becky had a history of suffering from migraines but her symptoms worsened in 2012 when she was just 21 years old. CT and MRI scans showed a small lesion on her brain which could have been caused by a number of different diagnoses. A Neurosurgeon at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust performed a brain biopsy to determine the diagnosis.
Becky was referred to Professor Brown who, she says, told her that without treatment, she had six to 12 months to live. Becky was commenced on neoadjuvant chemotherapy before commencing aggressive radiotherapy and chemotherapy treatment. This treatment affected her profoundly. From 2013 until 2024, she was commenced on adjuvant temozolomide chemotherapy every month. She says that she was told she would need to remain on chemotherapy for life, otherwise she would likely die.
Becky has conceived naturally twice during the period, requiring her to take breaks from her chemotherapy treatment. However, she was quickly restarted following both births, despite scans of her brain remaining stable while not on chemotherapy.
Independent expert reviews have concluded that she was initially misdiagnosed and that, rather than a brain tumour, her diagnosis was most likely to be tumefactive demyelination — a condition linked to multiple sclerosis. The review concluded that she received over 100 cycles of unnecessary temozolomide chemotherapy.
In 2019, under UHCW’s care, Michael was diagnosed with a low-grade tumour, having previously suffered from seizures. Following surveillance, he was told in 2020 that the tumour was transforming into high grade and following surgery it was diagnosed as a grade 4 glioblastoma.
The hospital’s oncology team then offered him radiotherapy and six cycles of temozolomide chemotherapy. Following Michael’s sixth cycle, his care was transferred to Professor Ian Brown. Professor Brown wasn’t present during consultations and Michael says he was only ever seen by a clinical nurse specialist.
Michael received an additional 22 cycles of temozolomide chemotherapy under the care of Professor Brown, despite his scans being stable. He had very young children at the time of diagnosis.
His treatment ceased at his own request in January 2024 due to the side effects that he was experiencing, which included extreme fatigue and low mood. It was through seeing news media reports of mistreatment — and not through disclosure by the Trust itself — that Michael learned that he should not have remained on treatment for such a lengthy period of time.
We understand how difficult it can be to process the news that your treatment may have been unnecessary. We're experts in medical negligence relating to chemotherapy treatments and are the only solicitors to have been working on these cases — and very closely with the Trust and its solicitors — since April 2024. This has given us a significant amount of in-depth knowledge into the practices of Professor Ian Brown — the doctor who administered these negligent treatments — as well as internal processes within the Trust.
Talk to us today for a free, no obligation discussion. Our experts will sensitively and confidentially explain how we can support you through this process and empower you to seek accountability, win justice, rebuild your life and recover compensation.
We're available to come and meet you wherever you're located. Give us a call, send us an email or complete our contact form below.
You can also get in touch with our experts Fiona and Becky directly.

Fiona Tinsley
Fiona is a Partner in our litigation team and our head of medical negligence and serious personal injury.

Loading form...

Despite guidelines recommending a maximum of six chemotherapy cycles, Lucy was prescribed over 75 across seven years — long after her scans showed no evidence of progression.

Across the UK, neurosurgery and neuro-oncology services at several NHS Trusts have been subject to independent reviews, regulatory scrutiny and (in some cases) Police investigations.

Prolonged chemotherapy treatment at University Hospitals Coventry and Warwickshire has sadly had a devastating and irreversible impact on David's life.

Concerns about chemotherapy now point to systemic failings involving neuro-oncology clinicians, neurosurgeons, neuroradiologists and more at UHCW.

Patients affected by the extended use of adjuvant Temozolomide chemotherapy have received a letter from University Hospitals Coventry and Warwickshire NHS Trust.

We’re the only solicitors to have been working with patients affected by Prof Ian Brown's long-term Temozolomide chemotherapy treatments since April 2024.

Recent revelations have raised concerns about patients who were subjected to prolonged temozolomide chemotherapy treatments at the University Hospitals of Coventry and Warwickshire NHS Foundation Trust.

From building a family to creating Wills and trusts, buying or selling property, land or a business, planning for your succession or dealing with a crisis, it helps to have ready access to a multidisciplinary legal team that can support you with whatever life throws your way.

Discover what the PIDR is and why it's changing, as well as what this means for those affected by serious personal injury.

Find out how the law works and the available routes to safeguard your clinical negligence compensation from financial settlements in divorce proceedings.

Fiona Tinsley and Bill Braithwaite explain the teamwork approach we adopt to support clients and their families who've suffered from a serious injury.

Ever more athletes are speaking out about the dangers of RED-S — a serious health issue that can do lasting damage.

Our team details what went wrong and how we went about securing compensation.

Our medical negligence team provided pro-bono legal support to the family of a young man who was considered brain-dead.

Our medical negligence team achieved an out of court settlement for a client who underwent unnecessary vein surgery.

Our medical negligence team helped a client to achieve a six-figure settlement for a delay in diagnosis and treatment.

Our medical negligence team helped a 68-year-old man to be awarded £380,000 for a terminal oesophageal cancer diagnosis.

If your child has been impacted by lack of screening, delayed treatment or improper diagnosis, we can help.